Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials

Donna M. Peehl, Cristian T. Badea, Thomas L. Chenevert, Heike E. Daldrup-Link, Li Ding, Lacey E. Dobrolecki, A. Mc Garry Houghton, Paul E. Kinahan, John Kurhanewicz, Michael T. Lewis, Shunqiang Li, Gary D. Luker, Cynthia X. Ma, H. Charles Manning, Yvonne M. Mowery, Peter J. O’Dwyer, Robia G. Pautler, Mark A. Rosen, Raheleh Roudi, Brian D. RossKooresh I. Shoghi, Renuka Sriram, Moshe Talpaz, Richard L. Wahl, Rong Zhou

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


The availability of high-fidelity animal models for oncology research has grown enormously in recent years, enabling preclinical studies relevant to prevention, diagnosis, and treatment of cancer to be undertaken. This has led to increased opportunities to conduct co-clinical trials, which are studies on patients that are carried out parallel to or sequentially with animal models of cancer that mirror the biology of the patients’ tumors. Patient-derived xenografts (PDX) and genetically engineered mouse models (GEMM) are considered to be the models that best represent human disease and have high translational value. Notably, one element of co-clinical trials that still needs significant optimization is quantitative imaging. The National Cancer Institute has organized a Co-Clinical Imaging Resource Program (CIRP) network to establish best practices for co-clinical imaging and to optimize translational quantitative imaging methodologies. This overview describes the ten co-clinical trials of investigators from eleven institutions who are currently supported by the CIRP initiative and are members of the Animal Models and Co-clinical Trials (AMCT) Working Group. Each team describes their corresponding clinical trial, type of cancer targeted, rationale for choice of animal models, therapy, and imaging modalities. The strengths and weaknesses of the co-clinical trial design and the challenges encountered are considered. The rich research resources generated by the members of the AMCT Working Group will benefit the broad research community and improve the quality and translational impact of imaging in co-clinical trials.

Original languageEnglish
Pages (from-to)657-680
Number of pages24
JournalTomography (Ann Arbor, Mich.)
Issue number2
StatePublished - Apr 2023


  • animal models
  • breast cancer
  • co-clinical trials
  • colorectal cancer
  • imaging
  • lung cancer
  • myelofibrosis
  • osteosarcoma
  • pancreatic cancer
  • prostate cancer
  • sarcoma


Dive into the research topics of 'Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials'. Together they form a unique fingerprint.

Cite this